ORAL VINORELBINE IN COMBINATION WITH TRASTUZUMAB AS A FIRST LINE THERAPY OF METASTATIC OR LOCALLY ADVANCED HER2-POSITIVE BREAST CANCER

被引：0
|
作者：
Farhat, Fadi [3 ]
Kattan, Joseph [2 ]
Ghosn, Marwan [1 ]
机构：
[1] St Joseph Univ, Fac Med, Hematol Oncol, Beirut, Lebanon
[2] Hotel Dieu France Univ Hosp, Hematol Oncol, Beirut, Lebanon
[3] Lebanese Univ, Hematol Oncol, Beirut, Lebanon
来源：
BREAST | 2015年 / 24卷
关键词：
D O I：
10.1016/S0960-9776(15)30073-4
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
PO61
引用
收藏
页码：S42 / S43
页数：5
相关论文
共 50 条
  • [1] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced HER2-positive breast cancer
    Ghosn, M.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    El-Mouhebb, M.
    Mourad, C.
    Farhat, F.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S182 - S183
  • [2] Oral vinorelbine in combination with trastuzumab as a first line therapy of metastatic or locally advanced Her2-positive breast cancer
    Farhat, F.
    Kattan, J.
    Chahine, G.
    Makdessi, J.
    Bitar, N.
    Ghosn, M.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S281 - S281
  • [3] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Farhat, Fadi
    Kattan, Joseph G.
    Ghosn, Marwan
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2016, 77 (05) : 1069 - 1077
  • [4] Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer
    Fadi Farhat
    Joseph G. Kattan
    Marwan Ghosn
    Cancer Chemotherapy and Pharmacology, 2016, 77 : 1069 - 1077
  • [5] Interim safety of pertuzumab in combination with trastuzumab and vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E.
    Lopez-Vega, J. M.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S178 - S179
  • [6] Evaluation of trastuzumab, docetaxel and capecitabine as first-line therapy for HER2-positive locally advanced or metastatic breast cancer
    Wardley, A.
    Anton-Torres, A.
    Pivot, X.
    Morales-Vasquez, F.
    Dias, Zetina L.
    Gaui, M.
    Otero Reyes, D.
    Jassem, J.
    Button, P.
    Bell, R.
    BREAST CANCER RESEARCH AND TREATMENT, 2007, 106 : S33 - S33
  • [7] Safety of pertuzumab plus trastuzumab plus vinorelbine for first-line treatment of patients with HER2-positive locally advanced or metastatic breast cancer
    Perez, E. A.
    Lopez-Vega, J. M.
    Del Mastro, L.
    Petit, T.
    Zamagni, C.
    Freudensprung, U.
    Bastiere-Truchot, L.
    Walker, R.
    Andersson, M.
    CANCER RESEARCH, 2013, 73
  • [8] Phase II Study of a Triple Combination of Oral Vinorelbine, Capecitabine and Trastuzumab as First-line Treatment in HER2-positive Metastatic Breast Cancer
    Chan, Arlene
    Conte, Pier-Franco
    Petruzelka, Lubos
    Tubiana-Mathieu, Nicole
    Ganju, Vinod
    Llombart, Antonio
    Espie, Marc
    Majois, Francoise
    Gil, Miguel Gil
    Vaissiere, Nathalie
    Villanova, Gustavo
    ANTICANCER RESEARCH, 2013, 33 (06) : 2657 - 2664
  • [9] Trastuzumab as first-line therapy in HER2-positive metastatic breast cancer patients
    Del Mastro, Lucia
    Lambertini, Matteo
    Bighin, Claudia
    Levaggi, Alessia
    D'Alonzo, Alessia
    Giraudi, Sara
    Pronzato, Paolo
    EXPERT REVIEW OF ANTICANCER THERAPY, 2012, 12 (11) : 1391 - 1405
  • [10] First line therapy of metastatic or locally advanced HER2-positive breast cancer: Update of the HERNATA study
    Langkjer, S. T.
    Lidbrink, E.
    Bjerre, K.
    Wist, E.
    Andersson, M.
    EUROPEAN JOURNAL OF CANCER, 2013, 49 : S420 - S420
12345